BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 16614610)

  • 1. [Anti-TNF alpha in the treatment of psoriatic arthritis].
    Claudepierre P; Wendling D; Cohen JD
    Presse Med; 2006 Apr; 35(4 Pt 2):647-55. PubMed ID: 16614610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infliximab treatment in psoriatic arthritis: our experience.
    Rioda WT; Adorni G
    Acta Biomed; 2006 Aug; 77(2):95-102. PubMed ID: 17172189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biologic therapy of psoriatic arthritis.
    Gladman DD
    Reumatismo; 2007; 59 Suppl 1():85-7. PubMed ID: 17828353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Off-label dermatologic uses of anti-TNF-a therapies.
    Alexis AF; Strober BE
    J Cutan Med Surg; 2005 Dec; 9(6):296-302. PubMed ID: 16699906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [New drugs and treatment strategies for rheumatoid arthritis].
    Fantini F
    Recenti Prog Med; 2003 Sep; 94(9):361-79. PubMed ID: 12942798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psoriatic arthritis.
    Goupille P
    Joint Bone Spine; 2005 Dec; 72(6):466-70. PubMed ID: 16310398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy.
    Rudwaleit M; Van den Bosch F; Kron M; Kary S; Kupper H
    Arthritis Res Ther; 2010; 12(3):R117. PubMed ID: 20553600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Should we be afraid of the anti-TNFalpha drugs in 2008?].
    Gaudin P
    Rev Med Interne; 2008 Dec; 29(12):971-4. PubMed ID: 18571291
    [No Abstract]   [Full Text] [Related]  

  • 9. [Biologicals in the treatment of rheumatic diseases].
    Scherer HU; Burmester GR
    Dtsch Med Wochenschr; 2006 Oct; 131(41):2279-85. PubMed ID: 17036270
    [No Abstract]   [Full Text] [Related]  

  • 10. Tumour necrosis factor inhibitors.
    Nash PT; Florin TH
    Med J Aust; 2005 Aug; 183(4):205-8. PubMed ID: 16097922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug retention rates and treatment discontinuation among anti-TNF-α agents in psoriatic arthritis and ankylosing spondylitis in clinical practice.
    Fabbroni M; Cantarini L; Caso F; Costa L; Pagano VA; Frediani B; Manganelli S; Galeazzi M
    Mediators Inflamm; 2014; 2014():862969. PubMed ID: 25110401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials.
    Saad AA; Symmons DP; Noyce PR; Ashcroft DM
    J Rheumatol; 2008 May; 35(5):883-90. PubMed ID: 18381787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Biological agents in treatment of psoriatic arthritis].
    Lewicki M; Dutkiewicz B; Widuchowska M; Kucharz EJ
    Pol Merkur Lekarski; 2008 Jul; 25(145):97-100. PubMed ID: 18839626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis.
    Tobin AM; Kirby B
    BioDrugs; 2005; 19(1):47-57. PubMed ID: 15691217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Recommendations for the appropriate use of anti-TNFalpha therapy in patients with psoriatic arthritis. Italian Rheumatology Society].
    Salvarani C; Olivieri I; Cantini F; Marchesoni A; Punzi L; Scarpa R; Matucci-Cerinic M
    Reumatismo; 2004; 56(3):133-4, 136-8. PubMed ID: 15470517
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy of antitumor necrosis factor(α) agents on patients with ankylosing spondylitis.
    Ren L; Li J; Luo R; Tang R; Zhu S; Wan L
    Am J Med Sci; 2013 Dec; 346(6):455-61. PubMed ID: 23715113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of severe psoriasis with TNF antagonists. Adalimumab, etanercept and infliximab.
    Mössner R; Reich K
    Curr Probl Dermatol; 2009; 38():107-136. PubMed ID: 19710553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction of biological agent dose in rheumatic diseases: descriptive analysis of 153 patients in clinical practice conditions.
    Inciarte-Mundo J; Hernández MV; Rosario V; Ruiz-Esquide V; Cabrera-Villalba S; Ramírez J; Cañete JD; Sanmartí R
    Reumatol Clin; 2014; 10(1):10-6. PubMed ID: 23876791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [TNF-alpha inhibitors].
    Fain O
    Rev Prat; 2003 Nov; 53(18):1989-90. PubMed ID: 15008210
    [No Abstract]   [Full Text] [Related]  

  • 20. [Anti-TNF alpha in the treatment of rheumatoid arthritis and ankylosing spondylitis].
    Lanfant-Weybel K; Lequerré T; Vittecoq O
    Presse Med; 2009 May; 38(5):774-87. PubMed ID: 19327945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.